Photo from wikipedia
Abstract Background To illustrate the accurate location of Poly-ADP-ribose polymerase inhibitor (PARPi) as the first-line maintenance therapy in advanced ovarian cancer (AOC). Methods Search for eligible studies and calculate clinical… Click to show full abstract
Abstract Background To illustrate the accurate location of Poly-ADP-ribose polymerase inhibitor (PARPi) as the first-line maintenance therapy in advanced ovarian cancer (AOC). Methods Search for eligible studies and calculate clinical outcomes. Results PARPi as a first-line maintenance treatment significantly prolonged the BRCAmut population and the homologous recombination deficiency (HRD) positive population. Conclusion PARPi as first-line maintenance therapy significantly improves the progression-free survival in AOC, especially in the BRCAmut and HRD positive populations. PARPi has been becoming the standard first-line maintenance therapy for AOC.
Journal Title: Cancer Investigation
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!